GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Beryl Drugs Ltd (BOM:524606) » Definitions » Net-Net Working Capital

Beryl Drugs (BOM:524606) Net-Net Working Capital : ₹-3.12 (As of Mar. 2024)


View and export this data going back to 1994. Start your Free Trial

What is Beryl Drugs Net-Net Working Capital?

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. This is a conservative way of estimating the company's value.

Beryl Drugs's Net-Net Working Capital for the quarter that ended in Mar. 2024 was ₹-3.12.

The industry rank for Beryl Drugs's Net-Net Working Capital or its related term are showing as below:

BOM:524606's Price-to-Net-Net-Working-Capital is not ranked *
in the Drug Manufacturers industry.
Industry Median: 7
* Ranked among companies with meaningful Price-to-Net-Net-Working-Capital only.

Beryl Drugs Net-Net Working Capital Historical Data

The historical data trend for Beryl Drugs's Net-Net Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Beryl Drugs Net-Net Working Capital Chart

Beryl Drugs Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Net-Net Working Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only -11.28 -10.89 -9.92 -6.25 -3.12

Beryl Drugs Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Net-Net Working Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -6.25 - -3.57 - -3.12

Competitive Comparison of Beryl Drugs's Net-Net Working Capital

For the Drug Manufacturers - Specialty & Generic subindustry, Beryl Drugs's Price-to-Net-Net-Working-Capital, along with its competitors' market caps and Price-to-Net-Net-Working-Capital data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Beryl Drugs's Price-to-Net-Net-Working-Capital Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Beryl Drugs's Price-to-Net-Net-Working-Capital distribution charts can be found below:

* The bar in red indicates where Beryl Drugs's Price-to-Net-Net-Working-Capital falls into.



Beryl Drugs Net-Net Working Capital Calculation

Beryl Drugs's Net-Net Working Capital (NNWC) per share for the fiscal year that ended in Mar. 2024 is calculated as

Net-Net Working Capital(A: Mar. 2024 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(6.613+0.75 * 75.839+0.5 * 12.602-85.629
-0-0)/5.0717
=-3.12

Beryl Drugs's Net-Net Working Capital (NNWC) per share for the quarter that ended in Mar. 2024 is calculated as

Net-Net Working Capital(Q: Mar. 2024 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(6.613+0.75 * 75.839+0.5 * 12.602-85.629
-0-0)/5.0717
=-3.12

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full.

In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

This is a conservative way of estimating the company's value.


Beryl Drugs  (BOM:524606) Net-Net Working Capital Explanation

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their net-net value. They are collected under our Net-Net screener.


Beryl Drugs Net-Net Working Capital Related Terms

Thank you for viewing the detailed overview of Beryl Drugs's Net-Net Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


Beryl Drugs (BOM:524606) Business Description

Traded in Other Exchanges
N/A
Address
133, Kanchan Bagh, Ground Floor, Indore, MP, IND, 452001
Beryl Drugs Ltd is a pharmaceutical company principally engaged in the manufacturing and marketing of allopathic pharmaceutical preparations. It also provides contract manufacturing services and veterinary products. It offers manufacturing options for product requirements like small-volume injectables in liquid form, small-volume injectables in dry powder form, eye and ear drops, intravenous fluids in poly pack and glass bottles, and veterinary medicines. The company earns the majority of its revenue from the sale of Bulk Drugs.

Beryl Drugs (BOM:524606) Headlines

No Headlines